EN DE
Watch Euroapi SAS for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Euroapi SAS (EAPI) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of Euroapi SAS stock €1.26, price €0.77, upside +63.2%, quality 47 out of 100. Rating: strongly undervalued. Calculated from audited financials with 13 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare FR · ISIN FR0014008VX5

ES Euroapi SAS logo Thin data Nov 9, 2026

Euroapi SAS

EAPI · PA
Cheap, value-trap risk

The stock costs 39% less than our calculation considers fair.

Fair value €1.26 · Strongly undervalued
Even on cautious assumptions the value is 62% above the price (€1.25).
Quality 47/100
Mixed vs. peers (4/10)
Weak Growth (revenue 5y −2.1 %/yr in EUR)
Loss-making · -40.8% net margin (TTM)
Negative free cash flow over the last twelve months
Narrow moat 13/100 · thin data
Thin data
Watch Euroapi SAS for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

€18.72 €0.7140 Fair Value €1.26 May 2022 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.

How to read this chart

54‑month range €0.7140 – €18.72 · fair‑value band €1.25 – €1.27 · the €0.7720 price screens below the €1.26 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.

Follow Euroapi SAS in your weekly email

Every Wednesday you see whether Euroapi SAS is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Euroapi S.A. develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use in France, Europe, Rest of Europe, North America, the Asia Pacific, and internationally.

Show moreShow less

The company offers contract development manufacturing organization for different classes of tides that uses solid phase chemistry; particle engineering; microbial fermentation; small molecules synthesis; prostaglandins; steroids and hormones; and opiates and controlled substances.

It provides their products to pharmaceutical, generic drug manufacturers, animal health product manufacturers, consumer health, nutrition and cosmetic product companies, biotech companies, and distribution companies, as well as contract development and manufacturing organization.

The company has a strategic alliance with Abolis Biotechnologies SAS for the development of microbial strains for the synthesis of key intermediates and 20 active ingredients. Euroapi S.A. was incorporated in 2020 and is based in Paris, France.

Stock analysis

Euroapi SAS (EAPI) currently trades at €0.7720, while our model-based Fair Value estimate is €1.26, implying the stock looks roughly 39% undervalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of €5.87 per share, and 12 of the 13 models we run sit above the €0.7720 price.

Bear case: the Multiples group reads lowest at €0.8300, and 1 of the 13 models stay below the price. Data coverage for this calculation is low.

Scenario range: €1.25 (bear) to €1.27 (bull), the price of €0.7720 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Euroapi SAS reported revenue of €848M in FY2025 versus €893M in FY2021, a compound −1.3%/yr. Reported net income was −€211M in FY2025.

Key figures

Market cap €73.1M Micro · P/S ratio 0.10 · EPS (TTM) €−3.42 · Net margin −40.8% · Return on equity −40.0% · Return on assets (EBIT) −4.5% (5-year average) · Operating margin −2.9% · Revenue (TTM) €795M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 13 out of 100 (low confidence).

What moves the price

The share trades about 77% below its 52-week high and 8% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 63%, EAPI screens cheaper than that median.

Fair Value models

Bear €1.25 Fair Value €1.26 Bull €1.27
Price €0.7720 · Upside +63.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF €4.96 €5.87 €7.30 80
Growth DCF €5.04 €5.89 €7.14 77
5Y EBITDA Exit €9.85 €14.90 €21.59 72
All 13 models by family
DCF Models
FCF DCF €4.96 €5.87 €7.30 80
5Y Revenue Exit €3.13 €3.31 €3.56 71
5Y EBITDA Exit €9.85 €14.90 €21.59 72
10Y Revenue Exit €4.02 €4.23 €4.38 66
10Y EBITDA Exit €7.39 €10.13 €13.08 67
Earnings-Based
EPV €1.25 €1.26 €1.27 70
Multiples
EV/EBIT €0.7500 €0.8300 €0.9100 63
EV/EBITDA €16.15 €21.36 €26.57 64
EV/Revenue €0.6800 €0.7500 €0.8300 52
Asset-Based
NCAV (Graham) €1.74 €2.63 €3.29 52
Growth DCF
Growth DCF €5.04 €5.89 €7.14 77
Rev-Margin DCF €3.13 €3.42 €3.85 71
Economic Profit
ROIC Compounder €1.25 €1.26 €1.27 70

Open the full fair value analysis →

Quality Score breakdown

Overall quality 47/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 13
How much profit the company makes from its sales and capital
Quality Growth 45
Are margins and returns getting better?
Cashflow 32
Do the profits arrive as real cash?
Financial strength 50
Debt, balance sheet and risk of trouble
Investment 87
Does it invest with discipline instead of growing at any price?
Low Volatility 32
How calm the share price moves, does not count
Price momentum 7
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 81
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 18/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−7.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.1%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1.1% (2020) → 0.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch EAPI, get fair value alerts →

Compare Euroapi SAS with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 551 stocks

Beats the industry median on 4/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 47 · Below median
Fair Value upside +63.2% · Top 25%
Profitability
Return on assets −16.2% · Bottom 25%
Net margin (12 months) −40.8% · Bottom 25%
Operating margin (12 months) −2.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −14.0% · Bottom 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 0.09× · Cheapest 25%
P/S (12 months) 0.09× · Cheapest 25%
Price / free cash flow (fiscal year) 1.6× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 15
FUTURE (revenue growth)0 · sector 25
PAST (return on equity)0 · sector 29
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $79.40 $113.53 +43% vs EAPI
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥49.23 ¥55.21 +12% vs EAPI
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,905 ₹1,947 +2% vs EAPI
Haleon plc HLN $9.14 $8.61 −6% vs EAPI
Merck KGaA MRK €149.20 €109.18 −27% vs EAPI
Galderma Group GALD CHF 190.65 CHF 109.86 −42% vs EAPI
Takeda Pharmaceutical Company TAK $21.02 $11.31 −46% vs EAPI
Teva Pharmaceutical Industries Limited TEVA $42.61 $20.74 −51% vs EAPI
Sandoz Group SDZ CHF 84.46 CHF 39.70 −53% vs EAPI
Divi's Laboratories Limited DIVISLAB ₹11,566 ₹1,567 −86% vs EAPI

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Euroapi SAS: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Euroapi SAS Fair Value". https://www.fairvalue-calculator.com/stock/EAPI

Frequently asked questions

Is Euroapi SAS (EAPI) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of €1.26 versus a price of €0.7720, about +63% upside (undervalued).
What is the fair value of EAPI?
Our model-based fair value for Euroapi SAS is €1.26 (as of Nov 9, 2026), built from audited fundamentals. The current price: €0.7720.
What is the quality score of EAPI?
Euroapi SAS has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Euroapi SAS (EAPI)?
Our model-based price target is the fair value of €1.26 (as of Nov 9, 2026) from 13 valuation models. Cautious scenario €1.25, optimistic scenario €1.27. It is a calculation from audited fundamentals, not an analyst target.
What is the Euroapi SAS stock forecast for 2026?
Our models put fair value at €1.26, about +63% upside versus a price of €0.7720 (undervalued). Cautious scenario €1.25, optimistic scenario €1.27. The calculation is refreshed regularly with new filings.
What is the revenue of Euroapi SAS (EAPI)?
Euroapi SAS reported trailing-twelve-month revenue of about €795M (latest available figure, as of Nov 9, 2026).
What is the intrinsic value of Euroapi SAS (EAPI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Euroapi SAS it is €1.26 per share (as of Nov 9, 2026), against a price of €0.7720. It is the blended result of 13 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit).
Is Euroapi SAS stock overvalued or undervalued in 2026?
As of Nov 9, 2026, EAPI trades below its calculated fair value: price €0.7720, fair value €1.26, a gap of about +63% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of EAPI?
No. The price is what the market pays today (€0.7720); the fair value is what the company's own numbers justify (€1.26). For Euroapi SAS the two are €0.4880 per share apart. That gap is exactly why we show both numbers side by side.
How much is Euroapi SAS worth?
The market values Euroapi SAS at about €73.1M (market capitalisation, as of Nov 9, 2026). Per share that is €0.7720; our models calculate a fair value of €1.26 per share.
What do the bullish and bearish scenarios say about EAPI?
Our models span a range for Euroapi SAS: cautious scenario €1.25, base €1.26, optimistic €1.27 per share (as of Nov 9, 2026, price €0.7720). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Euroapi SAS (EAPI)?
Balance-sheet figures for Euroapi SAS (as of Nov 9, 2026): return on equity −40.0%. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is EAPI from its 52-week high?
Euroapi SAS trades at €0.7720, about 77% below its 52-week high of €3.36 and 8% above the low of €0.7140 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of €1.26 is for.
Which stocks are comparable to Euroapi SAS?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Euroapi SAS stock attractive at the current price?
The data as of Nov 9, 2026: price €0.7720, calculated fair value €1.26 (+63%), Quality Score 47/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of EAPI calculated?
We run Euroapi SAS through 13 models from 6 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit. Every model gets the same audited fundamentals; the fair value of €1.26 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.7% above its aggregate fair value. Euroapi SAS currently trades 39% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Euroapi SAS (EAPI)?
The closing price on Nov 9, 2026 was €0.7720. Our model-based fair value is €1.26, about +63% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Euroapi SAS right now?
The large discount to fair value meets weak quality (47/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (€1.25). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. The models converge in a tight band (€1.25 to €1.27), unusually little disagreement for a valuation.

Key figures of Euroapi SAS

How large is the market capitalisation of Euroapi SAS (EAPI)?
The market capitalisation of Euroapi SAS is €73.1M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Euroapi SAS (EAPI)?
The price-to-sales ratio of Euroapi SAS is 0.10 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Euroapi SAS (EAPI)?
Earnings per share at Euroapi SAS are €−3.42. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Euroapi SAS (EAPI)?
The net margin of Euroapi SAS is −40.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Euroapi SAS (EAPI)?
The return on equity (ROE) of Euroapi SAS is −40.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Euroapi SAS (EAPI)?
On an EBIT basis the return on assets of Euroapi SAS is −4.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Euroapi SAS (EAPI)?
The operating margin of Euroapi SAS is −2.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Euroapi SAS (EAPI)?
Revenue at Euroapi SAS is growing −14.0% versus a year earlier (3y avg −4.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Euroapi SAS (EAPI)?
Earnings per share at Euroapi SAS are growing +267% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Euroapi SAS (EAPI) generate?
The free cash flow of Euroapi SAS is €47.0M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Euroapi SAS (EAPI) hold?
Euroapi SAS holds more cash than debt, €48.4M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Euroapi SAS in the live analysis

One click puts Euroapi SAS on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.